View it as a bio-tech start-up with $22M in start-up funds looking at developing a new medical product (TAVR) so expenditure should be back to the old AHZ days of $4M per year......dreaming?
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-114
-
- There are more pages in this discussion • 176 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.68 |
Change
0.080(0.43%) |
Mkt cap ! $357.9M | |||
| Open | High | Low | Value | Volume |
| $18.62 | $18.68 | $18.62 | $53.20K | 2.857K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $18.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.62 | 100 | 1 |
View Market Depth
| Last trade - 10.51am 24/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |